Protocol Ledger

NCT03817502 · Phase III · RECRUITING

Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

Interventional Phase III clinical trial protocol NCT03817502 sponsored by Gedeon Richter Plc in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-06-06 Enrollment: 330 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03817502
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)330 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03817502
Protocol FieldVerified Registry Value
NCT IdentifierNCT03817502
Consolidated Lead SponsorGedeon Richter Plc
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment330 participants (ESTIMATED)
Registered Start Date2019-06-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03817502
Hospital Research SiteLocationSite Profile
ProScience Research GroupCulver City, CAOpen Hospital Dossier ->
Atlanta Center for Medical ResearchAtlanta, GAOpen Hospital Dossier ->
University of CincinnatiCincinnati, OHOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI